Noticias

Roche's Wilserdly-Everolimus Gets FDA Approval For ESR1-Mutated Advanced Breast Cancer

NASDAQ

(RTTNews) - Roche Holding AG (RHHBY) said the U.S. Food and Drug Administration approved Wilserdly, or giredestrant, with everolimus for adults with estrogen receptor-positive, HER2-negative, ESR1-mutated advanced or metastatic breast cancer.

Leer el informe completo de Veytics

Mostramos la idea principal publicamente. Crea una cuenta gratis para seguir leyendo el articulo completo, guardarlo, comentarlo y conectarlo con contexto de mercados y OSINT.